Nurix Therapeutics is trading at $15.18, down 40.01%, after Sanofi stopped the Phase 1 trial and terminated SAR448272 development.
- SAR448272 is Sanofi’s partnered oral STAT6 degrader; Nurix no longer expects program-related milestones or royalties, while other Sanofi-licensed programs remain active.
- Jefferies lowered its price target from $45 to $36, maintaining a Buy rating. Biotech and major indexes were higher, making broad-market weakness an unlikely explanation for the company-specific drop.